Literature DB >> 35304385

Optimisation of strategies for management of heart failure with preserved ejection fraction.

Oscar Jolobe1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35304385      PMCID： PMC8966816          DOI： 10.7861/clinmed.Let.22.2.4

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   5.410


× No keyword cloud information.
  11 in total

1.  SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.

Authors:  Yumei Ye; Mandeep Bajaj; Hsiu-Chiung Yang; Jose R Perez-Polo; Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2017-04       Impact factor: 3.727

2.  Revisiting the risks of incident atrial fibrillation: a narrative review. Part 1.

Authors:  Gaurav Panchal; Maria Mahmood; Gregory Y H Lip
Journal:  Kardiol Pol       Date:  2019-04-25       Impact factor: 3.108

Review 3.  Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition.

Authors:  Iqra Hameed; Shariq R Masoodi; Shahnaz A Mir; Mudasar Nabi; Khalid Ghazanfar; Bashir A Ganai
Journal:  World J Diabetes       Date:  2015-05-15

4.  Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction.

Authors:  Rajan S Pooni; Tevfik F Ismail
Journal:  Clin Med (Lond)       Date:  2022-01       Impact factor: 2.659

5.  Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT.

Authors:  Bharathi Upadhya; James J Willard; Laura C Lovato; Michael V Rocco; Cora E Lewis; Suzanne Oparil; William C Cushman; Jeffrey T Bates; Natalie A Bello; Gerard Aurigemma; Karen C Johnson; Carlos J Rodriguez; Dominic S Raj; Anjay Rastogi; Leonardo Tamariz; Alan Wiggers; Dalane W Kitzman
Journal:  Circ Heart Fail       Date:  2021-11-26       Impact factor: 8.790

6.  Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.

Authors:  Tatjana S Potpara; Marija M Polovina; Marina M Licina; Jelena M Marinkovic; Gregory Y H Lip
Journal:  Eur J Heart Fail       Date:  2013-01-09       Impact factor: 15.534

7.  Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.

Authors:  Kazuhiro Yamamoto; Tohru Masuyama; Yasushi Sakata; Nagahiro Nishikawa; Toshiaki Mano; Junichi Yoshida; Takeshi Miwa; Motoaki Sugawara; Yukihiro Yamaguchi; Tomomi Ookawara; Keiichiro Suzuki; Masatsugu Hori
Journal:  Cardiovasc Res       Date:  2002-07       Impact factor: 10.787

8.  Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation.

Authors:  Elsayed Z Soliman; Akm F Rahman; Zhu-Ming Zhang; Carlos J Rodriguez; Tara I Chang; Jeffrey T Bates; Lama Ghazi; Joseph L Blackshear; Michel Chonchol; Lawrence J Fine; Walter T Ambrosius; Cora E Lewis
Journal:  Hypertension       Date:  2020-05-04       Impact factor: 10.190

9.  Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model.

Authors:  Seul Gee Lee; Seung Jun Lee; Jung Jae Lee; Jung Sun Kim; Oh Hyun Lee; Choong Ki Kim; Darae Kim; Yong Ho Lee; Jaewon Oh; Seil Park; Ok Hee Jeon; Sung Jin Hong; Chul Min Ahn; Byeong Keuk Kim; Young Guk Ko; Donghoon Choi; Myeong Ki Hong; Yangsoo Jang
Journal:  Korean Circ J       Date:  2020-02-12       Impact factor: 3.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.